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Summary
Background Few treatments with a distinct mechanism of action are available for patients with platinum-refractory 
advanced or metastatic urothelial carcinoma. We assessed the efficacy and safety of treatment with docetaxel plus 
either ramucirumab—a human IgG1 VEGFR-2 antagonist—or placebo in this patient population.
Methods We did a randomised, double-blind, phase 3 trial in patients with advanced or metastatic urothelial carcinoma 
who progressed during or after platinum-based chemotherapy. Patients were enrolled from 124 sites in 23 countries. 
Previous treatment with one immune-checkpoint inhibitor was permitted. Patients were randomised (1:1) using an 
interactive web response system to receive intravenous docetaxel 75 mg/m² plus either intravenous ramucirumab 
10 mg/kg or matching placebo on day 1 of repeating 21-day cycles, until disease progression or other discontinuation 
criteria were met. The primary endpoint was investigator-assessed progression-free survival, analysed by intention-to-
treat in the first 437 randomised patients. This study is registered with ClinicalTrials.gov, number NCT02426125.
Findings Between July, 2015, and April, 2017, 530 patients were randomly allocated either ramucirumab plus docetaxel 
(n=263) or placebo plus docetaxel (n=267). Progression-free survival was prolonged significantly in patients allocated 
ramucirumab plus docetaxel versus placebo plus docetaxel (median 4·07 months [95% CI 2·96–4·47] vs 2·76 months 
[2·60–2·96]; hazard ratio [HR] 0·757, 95% CI 0·607–0·943; p=0·0118). A blinded independent central analysis was 
consistent with these results. An objective response was achieved by 53 (24·5%, 95% CI 18·8–30·3) of 216 patients 
allocated ramucirumab and 31 (14·0%, 9·4–18·6) of 221 assigned placebo. The most frequently reported treatment-
emergent adverse events, regardless of causality, in either treatment group (any grade) were fatigue, alopecia, 
diarrhoea, decreased appetite, and nausea. These events occurred predominantly at grade 1–2 severity. The frequency 
of grade 3 or worse adverse events was similar for patients allocated ramucirumab and placebo (156 [60%] of 258 vs 
163 [62%] of 265 had an adverse event), with no unexpected toxic effects. 63 (24%) of 258 patients allocated 
ramucirumab and 54 (20%) of 265 assigned placebo had a serious adverse event that was judged by the investigator to 
be related to treatment. 38 (15%) of 258 patients allocated ramucirumab and 43 (16%) of 265 assigned placebo died 
on treatment or within 30 days of discontinuation, of which eight (3%) and five (2%) deaths were deemed related to 
treatment by the investigator. Sepsis was the most common adverse event leading to death on treatment (four [2%] vs 
none [0%]). One fatal event of neutropenic sepsis was reported in a patient allocated ramucirumab. 
Interpretation To the best of our knowledge, ramucirumab plus docetaxel is the first regimen in a phase 3 study to 
show superior progression-free survival over chemotherapy in patients with platinum-refractory advanced urothelial 
carcinoma. These data validate inhibition of VEGFR-2 signalling as a potential new therapeutic treatment option for 
patients with urothelial carcinoma. 
Funding Eli Lilly and Company.
Introduction
Platinum-based combination chemotherapy is standard 
front-line treatment for patients with advanced or 
metastatic urothelial carcinoma, with median overall 
survival of 11–15 months depending on the type of 
platinum chemotherapy that can be administered and 
baseline clinical prognostic factors.1–4 Despite objective 
responses of 40–70%, the duration of response is limited 
and most patients become refractory. Prognosis in 
refractory patients remains poor, with median overall 
survival with single-agent cytotoxic therapy of 
approximately 7 months.5
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Immune-checkpoint inhibitors targeting the pro gram-
med cell death 1 protein (PD-1) and its ligand (PD-L1) have 
shown clinical activity in patients with platinum-refractory 
urothelial carcinoma. Accelerated or full approval has 
been granted in the USA to five agents of this class based 
on objective responses of 15–21%.6–10 However, many 
patients treated with immune-checkpoint inhibitors have 
progressive disease as their best response, highlighting 
that other targets and treatments are needed.6–11
Vascular endothelial growth factor receptors (VEGFRs) 
1 and 2 and their ligands are important mediators of 
tumour angiogenesis and contribute to the pathogenesis 
and progression of urothelial carcinoma.11–19 Ramucirumab 
is an IgG1 monoclonal antibody that binds to the 
extracellular domain of VEGFR-2, competing with 
VEGFA, VEGFC, and VEGFD.20 There is strong rationale 
for testing the combination of ramucirumab and 
docetaxel in platinum-refractory urothelial carcinoma 
because preclinical data suggest synergy, and docetaxel is 
used widely as a single agent across the globe in this 
setting.21–24 In a randomised phase 2 study in patients with 
platinum-refractory advanced or metastatic urothelial 
carcinoma, ramucirumab plus docetaxel significantly 
improved median progression-free survival compared 
with docetaxel alone (5·4 months vs 2·8 months; hazard 
ratio [HR] 0·389, 95% CI 0·235–0·643; p=0·0002).13 
To confirm these results, we did a randomised phase 3 
trial (RANGE) in a similar patient population. Here, 
we report the primary analysis of investigator-assessed 
progression-free survival. Data for overall survival are 
immature at the time of this publication, prohibiting 
formal testing of objective response; overall survival 
outcomes will be reported once mature.
Methods
Study design and participants
We did a double-blind, multicentre, randomised, phase 3 
trial at 124 investigative sites in 23 countries (appendix 
pp 1–10). Full inclusion and exclusion criteria are provided 
in the study protocol (appendix pp 17–144). Briefly, patients 
aged 18 years or older were eligible for enrolment if they 
had: histologically or cytologically confirmed carcinoma of 
pure or predominant transi tional cell histology; locally 
advanced, unresectable, or metastatic disease extent; 
primary tumour originating from the bladder, urethra, 
ureter, or renal pelvis; and progression 14 months or less 
after platinum-containing chemotherapy (2 additional 
months were allowed for screening and patient 
identification over the standard 12 months).25 We permitted 
previous treatment with one immune-checkpoint inhibitor 
for patients who relapsed 24 months or  less from the end 
of a platinum-containing regimen, allowing an additional 
10 months for patients who received both platinum and 
immune-checkpoint inhibitors. Furthermore, patients had 
Research in context
Evidence before this study
We searched PubMed, abstracts of major oncology congresses 
(eg, American Society of Clinical Oncology [ASCO] and ASCO 
Genitourinary Cancer Symposium, and European Society for 
Medical Oncology), and clinical trial websites (including 
ClinicalTrials.gov), with no date restrictions, for preclinical 
reports and clinical trials (published in English) assessing 
chemotherapy, antiangiogenic therapies, and a combination of 
these methods in urothelial carcinoma. Multiple single-agent 
cytotoxic therapies (eg, docetaxel) showed modest activity in 
this patient population. Findings of a randomised phase 2 study 
(NCT01282463) in patients with platinum-refractory advanced 
or metastatic urothelial carcinoma showed that ramucirumab 
plus docetaxel significantly improved median progression-free 
survival versus docetaxel alone. Ramucirumab is an IgG1 
monoclonal antibody that binds to the extracellular domain of 
vascular endothelial growth factor receptor 2 (VEGFR-2), which 
is an important mediator of tumour angiogenesis. Thus, after 
review of the scientific literature and discussions with clinicians, 
researchers, and regulatory agencies, we undertook the phase 3 
RANGE trial of ramucirumab plus docetaxel versus placebo plus 
docetaxel in patients with platinum-refractory advanced or 
metastatic urothelial carcinoma. As our study protocol was 
being developed, emerging evidence suggested 
immune-checkpoint inhibitors targeting the programmed cell 
death 1 protein (PD-1) and its ligand (PD-L1) had clinical activity 
in a subset of patients with platinum-refractory urothelial 
carcinoma. Therefore, we included in our study patients who 
received one previous immune-checkpoint inhibitor.
Added value of this study
Compared with placebo plus docetaxel, ramucirumab plus 
docetaxel improved progression-free survival and objective 
responses without additive toxic effects or compromising 
quality of life in patients with platinum-refractory advanced or 
metastatic urothelial carcinoma. The responses reported in 
our phase 3 trial are in line with those noted with 
immune-checkpoint inhibitors in other studies.
Implications of all the available evidence
Taken together with results from the previous phase 2 study in a 
similar patient population, our phase 3 data show that inhibition 
of VEGFR-2-mediated signalling yields meaningful clinical 
activity in patients with platinum-refractory advanced or 
metastatic urothelial carcinoma. To the best of our knowledge, 
ramucirumab is the only antiangiogenic agent to show such 
activity in this patient population. Furthermore, RANGE is the 
first phase 3 trial as far as we are aware to show a 
progression-free survival advantage over chemotherapy alone in 
platinum-refractory advanced or metastatic urothelial 
carcinoma. These results confirm the benefit of adding an 
anti-VEGFR-2 antibody to standard chemotherapy in this setting 
and represent progress in the treatment of urothelial carcinoma.
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to have an Eastern Cooperative Oncology Group (ECOG) 
performance status of 0 or 1. Key exclusion criteria 
included more than one previous systemic chemotherapy 
in the relapsed or metastatic setting (previous systemic 
therapy in the perioperative setting was not judged a 
previous line); previous systemic taxane; untreated brain 
metastases; haemoglobin lower than 9 g/dL; and an 
arterial or venous thromboembolic event 6 months or less 
before randomisation.
The trial adhered to the Declaration of Helsinki, the 
International Conference on Harmonisation Guidelines 
for Good Clinical Practice, and applicable local regulations. 
The protocol was approved by the ethics committees of 
all participating centres, and patients provided written 
informed consent before study entry. An independent 
data monitoring committee assessed unblinded safety 
data throughout the study.
Randomisation and masking
Patients were randomly allocated treatment using an 
interactive web response system, with a computer-
generated random sequence. Randomisation was strat i-
fied by: geographic region (North America, east Asia, 
and Europe and the rest of the world); ECOG 
performance status at baseline (0 or 1); and visceral 
disease (yes or no), when visceral disease involved the 
liver, lung, bone, or a combination. Patients, study staff, 
and the study funder were unaware of treatment 
assignment. For masking, allocated treatments were 
volume equiv alent and in identical-appearing containers. 
Procedures
We administered intravenous docetaxel 75 mg/m² 
(60 mg/m² in Korea, Taiwan, and Japan) to all patients 
then either intravenous ramucirumab 10 mg/kg or 
placebo 10 mg/kg volume equivalent, as per the random 
assignment, on day 1 of a 21-day cycle. Treatments were 
continued until disease progression or unacceptable 
toxic effects. Docetaxel was restricted to six cycles; up to 
four additional cycles could be given after funder 
approval. There was no planned crossover on disease 
progression. We allowed dose modifications of any 
administered study drug, according to protocol-defined 
criteria. We permitted use of granulocyte-colony 
stimulating factors based on American Society of 
Clinical Oncology guidelines.26
We assessed tumour response radiographically 
according to Response Evaluation Criteria in Solid 
Tumors (RECIST) version 1.1 at baseline, every 6 weeks 
after randomisation for the first year, and then every 
12 weeks thereafter. Radiological assessments were 
analysed by investigators at local sites and reviewed by an 
independent blinded assessment group (BIOCLINICA, 
Princeton, NJ, USA). After discontinuation, we followed 
up patients for survival every 3 months. The appendix 
(pp 17–144) provides details of the timing of other 
assessments. We graded adverse events using National 
Cancer Institute (NCI) Common Terminology Criteria 
for Adverse Events (CTCAE) version 4.0. We assessed 
patient-reported outcomes using European Organisation 
for Research and Treatment of Cancer (EORTC) Quality 
of Life Questionnaire Core 30 (QLQ-C30) version 3.0 and 
the EQ-5D-5L questionnaire, which measure quality of 
life and health status, respectively. QLQ-C30 is scored on 
a scale from 0 to 100, according to the EORTC scoring 
manual, and the EQ-5D-5L index was calculated using 
the English value set.27 For QLQ-C30, we defined time to 
sustained deterioration as time from randomisation to 
the first 10 point or greater worsening with no subsequent 
on-therapy assessment that returned to or improved 
from baseline score.
Outcomes
The primary endpoint was progression-free survival as 
assessed by the investigator, defined as the time from 
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Prof Daniel P Petrylak, 
Yale School of Medicine, 
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daniel.petrylak@yale.edu
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727 patients assessed for eligibility
530 randomly assigned
197 excluded
 154 did not meet inclusion criteria
 21 withdrew
 7 died
 6 clinician’s decision
 2 adverse event
 7 other
263 assigned ramucirumab plus docetaxel
 (ITT population)
216 analysed for efficacy (ITT population*)
267 assigned placebo plus docetaxel
 (ITT population)
221 analysed for efficacy (ITT population*)
258 received any dose of assigned study treatment 
 (safety population)
209 discontinued study treatment
 121 progressive disease
 28 died
 24 adverse event
 17 withdrew
 14 clinician’s decision
 2 lost to follow-up
 3 other
265 received any dose of assigned study treatment 
 (safety population)
49 on study treatment at data cutoff 36 on study treatment at data cutoff 
229 discontinued study treatment
 173 progressive disease
 22 died
 13 withdrew
 8 adverse event
 7 clinician’s decision
 1 protocol deviation
 5 other
5 not treated
 3 did not meet inclusion criteria
 1 protocol deviation
 1 withdrew
2 not treated
 1 clinician’s decision
 1 did not meet inclusion criteria
Figure 1: Trial profile
ITT=intention to treat. *The primary analysis was done in the first 437 randomised patients.
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randomisation until first radiographic documentation of 
objective progression, or as death from any cause. 
Secondary endpoints included: overall survival, defined 
as the time from randomisation to death from any cause; 
objective response, defined as the proportion of patients 
with a best overall response of complete or partial 
response; disease control, defined as the proportion of 
patients with a best overall response of complete 
response, partial response, or stable disease; duration of 
response, defined as the first date of complete or partial 
response until the first date of objective progression, or 
death; safety; patient-reported outcomes; pharmaco-
kinetics of ramucirumab; and immuno genicity of 
ramucirumab. The appendix (pp 17–144) provides the 
full assessment schedule. Here, we report the primary 
analysis of investigator-assessed progression-free survival 
and data for all secondary analyses with the exception of 
overall survival, for which data were immature at the 
time of data cutoff.
Statistical analysis
We planned to enrol 524 patients in a 1:1 randomisation, 
with the primary analysis to be done when at least 
331 progression-free survival events were reported. 
We assumed 15% patient dropout and estimated that 
roughly 437 patients would be needed to reach 
331 progression-free survival events. The number of 
events provided 90% power to detect progression-free 
survival superiority of ramucirumab plus docetaxel 
versus placebo plus docetaxel, assuming an HR of 0·70 
with a two-sided α of 0·05. The sample size was also 
powered to show an overall survival superiority between 
the two treatment groups, with an assumed HR of 0·75 
for ramucirumab plus docetaxel versus placebo plus 
docetaxel with at least 382 events, power of 80%, and a 
two-sided type I error of 0·05.
We assessed progression-free survival and response in 
the first 437 patients of the intention-to-treat (ITT) 
Ramucirumab 
plus docetaxel 
(n=263)
Placebo plus 
docetaxel 
(n=267)
Age (years) 65 (34–86) 66 (32–83)
≥65 139 (53%) 152 (57%)
Sex
Men 213 (81%) 215 (81%)
Women 50 (19%) 52 (19%)
Ethnic origin
White 204 (78%) 204 (76%)
Asian 54 (21%) 61 (23%)
Other 3 (1%) 2 (<1%)
Missing 2 (<1%) 0
ECOG performance status
0 121 (46%) 125 (47%)
1 138 (52%) 142 (53%)
Missing 4 (2%) 0
Geographic region
North America 24 (9%) 24 (9%)
East Asia 53 (20%) 57 (21%)
Europe and rest of the world 186 (71%) 186 (70%)
Histology
Pure transitional cell 201 (76%) 209 (78%)
Mixed histology 55 (21%) 50 (19%)
Missing 7 (3%) 8 (3%)
Bladder as primary site of tumour 169 (64%) 170 (64%)
Visceral disease 182 (69%) 188 (70%)
Lung metastases 99 (38%) 121 (45%)
Liver metastases 78 (30%) 69 (26%)
Bone metastases 56 (21%) 53 (20%)
Adrenal gland 16 (6%) 12 (4%)
Kidney 12 (5%) 10 (4%)
Spleen 4 (2%) 5 (2%)
Other 35 (13%) 28 (10%)
Lymph-node-only metastases 52 (20%) 45 (17%)
Creatinine clearance (mL/min)
<60 106 (40%) 118 (44%)
≥60 151 (57%) 146 (55%)
Missing 6 (2%) 3 (1%)
(Table 1 continues in next column)
Ramucirumab 
plus docetaxel 
(n=263)
Placebo plus 
docetaxel 
(n=267)
(Continued from previous column)
Haemoglobin concentration <10 g/dL 37 (14%) 36 (13%)
Completion or discontinuation of 
most recent treatment <3 months
115 (44%) 122 (46%)
Bellmunt risk factors (n)*
0 61 (23%) 54 (20%)
1 85 (32%) 96 (36%)
2 69 (26%) 82 (31%)
3 47 (18%) 31 (12%)
4 1 (<1%) 4 (1%)
Previous adjuvant treatment
Adjuvant 38 (14%) 61 (23%)
Neoadjuvant 40 (15%) 37 (14%)
No previous adjuvant 168 (64%) 155 (58%)
Missing 17 (6%) 14 (5%)
Previous treatments†
Cisplatin-based 159 (60%) 182 (68%)
Carboplatin-based 95 (36%) 78 (29%)
Immune-checkpoint inhibitor 18 (7%)‡ 26 (10%)
Data are number of patients (%) or median (range). ECOG=Eastern Cooperative 
Oncology Group. *Bellmunt risk factors28,29 included liver metastases, 
haemoglobin <10 g/dL, ECOG performance status score >0, and time since 
completion or discontinuation of previous treatment of <3 months. †A summary 
of previous anticancer treatments is included in the appendix (p 13). ‡Among the 
first 437 randomised patients, one patient allocated ramucirumab received 
nivolumab or placebo in a previous clinical trial, but we do not know whether that 
patient actually received nivolumab, so they are not included in this total.
Table 1: Baseline demographics and treatment and disease 
characteristics (intention-to-treat population)
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population, which included all randomised patients. 
We used the full ITT population to assess 
patient-reported outcomes. We estimated progression-
free survival using the Kaplan-Meier method, and 
we compared outcomes between treatment groups 
using a stratified log-rank test. We estimated HRs and 
associated 95% CIs using a stratified Cox proportional 
hazard model. We summarised patient-reported 
outcome data descrip tively. We compared time to 
sustained deterior ation using a non-stratified log-rank 
test. We assessed safety in all patients who received at 
least one dose of study medication (safety population). 
We implemented a gatekeeping design to assess 
progression-free survival, overall survival, and objective 
response in a fixed sequential manner.
This study is registered with ClinicalTrials.gov, number 
NCT02426125.
Role of the funding source
The funder designed the trial, in collaboration with the 
scientific council (including DPP, RdW, KNC, CNS, HN, 
and TP), and was responsible for data management and 
statistical analysis. The funder interpreted data in 
collaboration with all authors and supported development 
of the report by providing medical writing and editorial 
assistance. The corresponding author had full access to 
all data in the study and all authors had final responsibility 
for the decision to submit for publication.
Results
Between July, 2015, and April, 2017, 727 patients were 
screened for study eligibility of whom 197 were excluded 
mainly for not meeting inclusion criteria (figure 1); 
530 patients were randomly allocated either 
ramucirumab plus docetaxel (n=263) or placebo plus 
docetaxel (n=267) and comprised the ITT population. 
Baseline charac teristics were balanced between treat-
ment groups in the ITT population (table 1; appendix 
p 13) and in the first 437 randomised patients (appendix 
pp 11, 12). 234 (44%) of 530 patients had two or 
more adverse prognostic risk factors, including liver 
metastases (n=147 [28%]), haemoglobin lower than 
10 g/dL (n=73 [14%]), ECOG performance status score 
greater than 0 (n=280 [53%]), and time since completion 
or discontinuation of previous therapy of less than 
3 months (n=237 [45%]; table 1). Five patients allocated 
ramucirumab and two assigned placebo did not receive 
study treatment; therefore, the safety population 
comprised 523 patients, of whom 258 were allocated 
ramucirumab and 265 were assigned placebo.
Data cutoff for the current analysis was April 21, 2017. 
At data cutoff, 49 (19%) of 263 patients allocated 
ramucirumab and 36 (13%) of 267 assigned placebo 
continued to receive study treatment (figure 1). Median 
duration of follow-up in the full ITT population was 
5·0 months (IQR 2·3–8·9). Median treatment duration 
was 12·1 weeks (IQR 6·0–21·0) with ramucirumab and 
9·9 weeks (6·0–20·9) with placebo. The median number 
of cycles of docetaxel was four (IQR 2–6) in patients 
allocated ramucirumab and three (2–6) in those assigned 
placebo (appendix p 14). 93 (36%) of 258 patients allocated 
ramucirumab and 84 (32%) of 265 assigned placebo 
completed at least six cycles of docetaxel therapy; median 
relative dose intensities were 98·3% (IQR 90·9–100·1) 
and 98·8% (92·9–100·1), respectively. Patients who 
continued with ramucirumab or placebo mono therapy 
after the end of docetaxel treatment (64 vs 60) received 
a median of three (IQR 2–7) additional cycles of 
ramucirumab and two (1–5) of placebo.
At data cutoff, 341 progression-free survival events 
had occurred in the first 437 patients of the ITT 
population, 158 (73%) of 216 allocated ramucirumab and 
183 (83%) of 221 assigned placebo (appendix p 15). 
Median progression-free survival was 4·07 months 
(95% CI 2·96–4·47) in patients allocated ramucirumab 
Number at risk
(number censored)
Ramucirumab plus
docetaxel
Placebo plus
docetaxel
216 (0)
221 (0)
132 (21)
124 (16)
96 (6)
77 (1)
40 (16)
34 (6)
28 (2)
19 (3)
19 (3)
7 (8)
12 (2)
3 (1)
4 (6)
2 (1)
1 (2)
2 (0)
0 (0)
0 (2)
HR 0·757 (95% CI 0·607–0·943)
Log-rank p=0·0118
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Figure 2: Kaplan-Meier plots for progression-free survival in the first 437 randomised patients 
(intention-to-treat population)
(A) Investigator-assessed. (B) Independent central review. HR=hazard ratio. 
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and 2·76 months (2·60–2·96) in those assigned placebo 
(stratified HR 0·757, 95% CI 0·607–0·943; p=0·0118; 
figure 2A). Estimated progression-free survival at 
12 months was 11·9% (95% CI 7·1–18·0) in patients 
allocated ramucirumab and 4·5% (1·5–10·1) in those 
assigned placebo. A blinded independent central 
analysis was consistent with these results, with median 
progression-free survival of 4·04 months (95% CI 
2·96–4·30) and 2·46 months (1·45–2·83), respectively 
(stratified HR 0·672, 95% CI 0·536–0·842; p=0·0005; 
figure 2B). In prespecified subgroup analyses of 
progression-free survival, addition of ramucirumab to 
docetaxel improved progression-free survival across most 
subgroups (figure 3).
Investigator-assessed objective responses in the first 
437 patients in the ITT population were achieved by 
HR (95% CI)Ramucirumab
Patients/events
Age (years)
 <65
 ≥65
Sex
 Male
 Female
Ethnic origin
 White
 Asian
Geographic region
 East Asia
 Europe and rest of world
 North America
Histological type
 Transitional cell
 Mixed
Primary disease site
 Urinary bladder
 Other
ECOG performance status at baseline
 0
 1
Visceral disease
 Yes
 No
Lymph node only disease
 Yes
 No
Liver metastases
 Yes
 No
Baseline haemoglobin (g/dL)
 <10
 ≥10
Time since most recent chemotherapy (months)
 <3
 ≥3
Risk factors (n)
 0
 1
 2
 3–4
Previous adjuvant therapy
 Adjuvant
 Neoadjuvant
 No previous adjuvant
Context of most recent therapy
 Adjuvant or neoadjuvant
 Metastatic disease
Previous platinum-based therapy
 Cisplatin
 Carboplatin
Previous immune-checkpoint inhibitor 
 Yes
 No
Overall
 
 103/74
 113/84
 175/134
 41/24
 159/115
 54/41
 53/40
 146/106
 17/12
 169/122
 40/33
 136/99
 77/59
 99/72
 113/85
 145/116
 68/42
 46/27
 170/131
 64/52
 152/106
 30/25
 181/133
 96/77
 115/80
 50/30
 67/47
 62/52
 37/29
 32/24
 28/18
 144/110
 37/27
 166/125
 134/98
 75/57
 14/10*
 197/147
 216/158
 
 102/87
 119/96
 176/148
 45/35
 160/134
 60/48
 57/46
 145/125
 19/12
 174/146
 42/33
 138/120
 83/63
 102/83
 119/100
 153/132
 68/51
 39/28
 182/155
 55/51
 166/132
 30/27
 190/156
 102/89
 113/88
 44/31
 80/67
 68/58
 29/27
 50/36
 34/28
 123/106
 50/36
 158/134
 149/121
 66/56
 19/17
 196/160
 221/183
 0·623 (0·455–0·853)
 0·901 (0·672–1·208)
 0·799 (0·631–1·011)
 0·607 (0·359–1·027)
 0·726 (0·564–0·933)
 0·848 (0·558–1·288)
 0·841 (0·549–1·288)
 0·660 (0·507–0·858)
 1·240 (0·549–2·799)
 0·694 (0·545–0·885)
 1·158 (0·711–1·887)
 0·684 (0·522–0·898)
 0·884 (0·619–1·261)
 0·725 (0·526–1·000)
 0·764 (0·572–1·021)
 0·862 (0·671–1·107)
 0·592 (0·390–0·898)
 0·542 (0·316–0·930)
 0·868 (0·688–1·097)
 0·694 (0·468–1·028)
 0·742 (0·574–0·960)
 0·954 (0·549–1·659)
 0·735 (0·583–0·928)
 0·738 (0·542–1·004)
 0·802 (0·592–1·088)
 0·766 (0·459–1·278)
 0·682 (0·468–0·994)
 0·772 (0·529–1·127)
 0·717 (0·421–1·222)
 1·019 (0·607–1·710)
 0·867 (0·476–1·577)
 0·673 (0·514–0·882)
 1·283 (0·776–2·119)
 0·658 (0·514–0·842)
 0·790 (0·604–1·032)
 0·709 (0·486–1·036)
 
 0·920 (0·409–2·067)
 0·777 (0·621–0·973)
 0·761 (0·615–0·943)
Placebo
Patients/events
1·00·40·2 1·4 2·01·2 1·60·80·6
Favours placeboFavours ramucirumab
Figure 3: Progression-free survival subgroup analyses in the first 437 randomised patients (intention-to-treat population)
ECOG=Eastern Cooperative Oncology Group. HR=hazard ratio. *One patient allocated ramucirumab received nivolumab or placebo in a previous clinical trial, but we 
do not know whether that patient actually received nivolumab, so they are not included in this total for subgroup analysis.
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53 (24·5%, 95% CI 18·8–30·3) of 216 patients allocated 
ramucirumab and 31 (14·0%, 9·4–18·6) of 221 assigned 
placebo (appendix p 15). These included nine (4%) 
complete responses in patients allocated ramucirumab 
and three (1%) in those assigned placebo. Objective 
responses by blinded independent central analysis were 
achieved by 48 (22·2%, 95% CI 16·7–27·8) of 
216 patients allocated ramucirumab and 28 (12·7%, 
8·3–17·1) of 221 assigned placebo. Because of the 
gatekeeping trial design, objective response superiority 
will be formally tested if the overall survival superiority 
test is positive. Median duration of response was 
5·65 months (95% CI 3·9–7·1) for patients allocated 
ramucirumab and 4·17 months (2·9–5·5) for those 
assigned placebo. Of patients who received a previous 
immune-checkpoint inhibitor, five (36%) of 14 allocated 
ramucirumab and two (11%) of 19 assigned placebo 
achieved an objective response to treatment. Disease 
control occurred in 137 (63·4%, 95% CI 57·0–69·8) of 
216 patients allocated ramucirumab and 124 (56·1%, 
49·6–62·7) of 221 assigned placebo. Most patients 
allocated ramucirumab (107 [64%] of 168) had a 
reduction in tumour burden (figure 4). Reductions in 
tumour burden were seen less frequently in patients 
allocated placebo (86 [47%] of 183). At data cutoff, overall 
survival results were not mature, with 219 events.
Compliance for completion of the questionnaires for 
patient-reported outcomes in the full ITT population 
was 97% in both treatment groups at baseline and was 
85% or higher at all on-therapy post-baseline visits. 
Mean scores for global quality of life and the EQ-5D-5L 
index were similar between treatment groups at baseline 
Figure 4: Best percentage change from baseline in tumour size for patients who had baseline and at least one post−baseline tumour size assessment 
(A) Ramucirumab plus docetaxel (n=168). (B) Placebo plus docetaxel (n=183). Best response assessed according to RECIST version 1.1. CR=complete response. 
NE=not evaluable. PD=progressive disease. PR=partial response. RECIST=Response Evaluation Criteria in Solid Tumors. SD=stable disease. 
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and were relatively unchanged over time, with no 
differences between treatment groups (figure 5). No 
difference was recorded in time to sustained 
deterioration in global quality of life (non-stratified 
HR 0·931, 95% CI 0·701–1·235; p=0·610).
After administration of ramucirumab 10 mg/kg every 
3 weeks in combination with docetaxel to patients with 
urothelial carcinoma, the geometric mean trough 
concentrations before doses two, three, and five were 
15 µg/mL, 23 µg/mL, and 34 µg/mL, respectively. 
These data are consistent with those from previous 
studies in which ramucirumab was administered to 
patients with various types of cancer using this 
regimen.30–32 Of 258 patients allocated ramucirumab who 
received treatment, 185 had serum samples analysed for 
the presence of anti-ramucirumab antibodies; 19 (10%) 
had positive samples at baseline and three (2%) had 
treatment-emergent anti-ramucirumab antibodies.
The most frequently reported treatment-emergent 
adverse events, regardless of causality, in either 
treatment group (any grade) were fatigue, alopecia, 
diarrhoea, decreased appetite, and nausea (table 2). 
These events occurred predominantly at grade 1–2 
severity. 156 (60%) of 258 patients allocated 
ramucirumab and 163 (62%) of 265 assigned placebo 
reported an adverse event of grade 3 or worse. No 
adverse event of grade 3 or worse was recorded that 
showed a difference in frequency of 5% or more in 
patients allocated ramucirumab compared with placebo. 
Grade 3 or worse anaemia was less common in patients 
allocated ramucirumab than in those assigned placebo 
(seven [3%] vs 28 [11%]), but the frequency of grade 3 or 
worse neutropenia was similar in both treatment groups 
(39 [15%] vs 36 [14%]). Use of granulocyte colony-
stimulating factor was similar in both treatment groups 
(106 [41%] of 258 allocated ramu cirumab and 112 [42%] 
of 265 assigned placebo). Adverse events of special 
interest, based on the known safety profile of other anti-
angiogenic therapies and previous clinical experience 
with ramucirumab, are shown in table 2. Grade 1–2 
events of epistaxis (36 [14%] vs 13 [5%]), hypertension 
(29 [11%] vs 12 [5%]), haematuria (27 [10%] vs 17 [6%]), 
and proteinuria (23 [9%] vs eight [3%]) were each 
reported more frequently in 258 patients allocated 
ramucirumab than in 265 assigned placebo. The 
frequency of venous (six [2%] vs 13 [5%]) and arterial 
(eight [3%] vs two [<1%]) thromboembolic events was 
low and similar in both treatment groups.
Adverse events leading to at least one dose adjustment 
(reduction, delay, or omission of any study drug) were 
reported in 88 (34%) of 258 patients allocated ramu-
cirumab and 82 (31%) of 265 assigned placebo. 
The most common adverse event leading to 
dose adjustments for ramucirumab compared with 
placebo was febrile neutro penia (11 [4%] vs ten [4%]). 
Adverse events leading to discontinuation of any study 
treatment occurred in 39 (15%) of 258 patients allocated 
ramucirumab and 19 (7%) of 265 assigned placebo; 
sepsis was the most common adverse event leading 
to discontinuation of any treatment (five [2%] vs 
none [0%]).
Serious adverse events were reported for 100 (39%) of 
258 patients allocated ramucirumab and 104 (39%) of 
265 assigned placebo; these events were deemed by the 
investigator to be related to study treatment in 63 (24%) 
and 54 (20%) patients, respectively. Including events 
related by the investigator to disease progression, adverse 
Figure 5: Patient-reported outcome scores by visit
Circles represent mean scores and bars represent SD, in patients completing the questionnaire and with a valid 
score for the scale. Data for treatment groups are offset along the x-axis for legibility, but assessment times were 
the same for both groups. (A) EORTC QLQ-C30 global quality of life; scores range from 0 to 100, with higher scores 
representing better quality of life. (B) EQ-5D-5L index; scores range from –0·281 to 1 (displayed as 0–1), with 
higher scores representing better health status. 
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events with an outcome of death on treatment or within 
30 days of discontinuation were reported for 38 (15%) of 
258 patients allocated ramucirumab and 43 (16%) of 
265 assigned placebo; these events were deemed by the 
investigator to be related to study treatment in eight (3%) 
and five (2%) patients, respectively. Sepsis was the most 
common adverse event leading to death on treatment 
(appendix p 16), occurring in four (2%) patients allocated 
ramucirumab and no patients assigned placebo. One fatal 
event of neutropenic sepsis was reported in a patient 
allocated ramucirumab.
Discussion
Findings of the RANGE trial show that addition of 
ramucirumab to docetaxel is associated with a significant 
improvement in progression-free survival in patients 
with platinum-refractory advanced urothelial carcinoma. 
In this advanced patient population, progression-free 
survival outcomes were consistent across almost all 
major subgroups examined and confirmed by blinded 
central review. 44% of patients in this trial had two or 
more adverse prognostic risk factors at baseline, 
including the presence of liver metastases.28,29 A con-
sistent progression-free survival benefit was seen for 
patients treated with ramucirumab plus docetaxel, 
irrespective of the number of associated risk factors, 
showing broad applicability of this regimen. The median 
progression-free survival of 2·76 months that was 
recorded with placebo plus docetaxel is consistent with 
historical data in the second-line setting, such that the 
noted improvement with ramucirumab plus docetaxel 
(4·07 months) was not attributable to underperformance 
of the control.5,13
Data for overall survival are immature at this time, 
precluding formal statistical analysis of objective response 
in accordance with the order of analyses specified in the 
statistical analysis plan. However, a higher proportion of 
patients allocated ramucirumab achieved an objective 
response compared with placebo (24·5% vs 14·0%), 
including nine complete responses with ramucirumab 
versus three with placebo, with non-overlapping 95% CIs. 
The objective response was consistent with findings of a 
phase 2 study of this treatment regimen and it was higher 
when compared indirectly with historical chemotherapy 
studies.5,13,23 The objective response recorded in patients 
allocated ramucirumab in our study is also in line with 
that seen with immune-checkpoint inhibitors in other 
studies, although duration of response is longer with 
immune-checkpoint inhibitors.6 Disease control was 
achieved by 63% of patients allocated ramucirumab in our 
study, which compares favourably with single-agent 
chemo therapy or immune-checkpoint inhibitors in other 
studies, underlining the active nature of this regimen in 
biomarker-unselected patients.6,13,33
The combination of ramucirumab and docetaxel 
revealed no unexpected safety findings. The most common 
toxic effects were of grade 1–2 severity and manageable 
with supportive care alone or with dose reductions, as 
shown by the high median relative dose-intensity for all 
study drugs. Overall, addition of ramucirumab to docetaxel 
was not associated with an increase in occurrence of 
grade 3 or worse toxic effects typically associated with 
docetaxel in this patient population. Consistent with 
phase 2 data,13 the most common haematological toxic 
effect in our study was neutropenia, reported at a similar 
frequency in both treatment groups; anaemia was less 
common in patients allocated ramucirumab. The 
frequency of toxic effects identified as potential class 
effects of antiangiogenic therapies—eg, grade 1–2 
Ramucirumab plus docetaxel 
(n=258)
Placebo plus docetaxel  
(n=265)
Any grade Grade ≥3 Any grade Grade ≥3
All adverse events
Any 244 (95%) 156 (60%) 251 (95%) 163 (62%)
Fatigue* 110 (43%) 20 (8%) 121 (46%) 25 (9%)
Alopecia 63 (24%) 0 92 (35%) 1 (<1%)
Diarrhoea 75 (29%) 7 (3%) 56 (21%) 7 (3%)
Decreased appetite 73 (28%) 8 (3%) 61 (23%) 5 (2%)
Nausea 63 (24%) 1 (<1%) 52 (20%) 3 (1%)
Stomatitis 61 (24%) 8 (3%) 29 (11%) 0
Pyrexia 42 (16%) 1 (<1%) 41 (15%) 1 (<1%)
Vomiting 38 (15%) 3 (1%) 37 (14%) 2 (<1%)
Neuropathy* 31 (12%) 0 43 (16%) 2 (<1%)
Constipation 29 (11%) 1 (<1%) 43 (16%) 1 (<1%)
Urinary-tract infection 32 (12%) 10 (4%) 38 (14%) 11 (4%)
Peripheral oedema 36 (14%) 0 30 (11%) 1 (<1%)
Dypnoea 30 (12%) 5 (2%) 30 (11%) 5 (2%)
Asthenia 26 (10%) 3 (1%) 22 (8%) 4 (2%)
Dysgeusia 30 (12%) 0 17 (6%) 0
Haematological adverse events
Neutropenia* 51 (20%) 39 (15%) 44 (17%) 36 (14%)
Febrile neutropenia 25 (10%) 25 (10%) 17 (6%) 17 (6%)
Anaemia 40 (16%) 7 (3%) 64 (24%) 28 (11%)
Leucopenia* 26 (10%) 17 (7%) 24 (9%) 21 (8%)
Adverse events of special interest
Bleeding or haemorrhage* 67 (26%) 8 (3%) 46 (17%) 12 (5%)
Epistaxis 36 (14%) 0 13 (5%) 0
Haematuria 27 (10%) 5 (2%) 17 (6%) 5 (2%)
Gastrointestinal haemorrhage 10 (4%) 2 (<1%) 10 (4%) 3 (1%)
Pulmonary haemorrhage 1 (<1%) 0 0 0
Hypertension* 29 (11%) 15 (6%) 12 (5%) 5 (2%)
Renal failure* 15 (6%) 8 (3%) 19 (7%) 2 (<1%)
Proteinuria 23 (9%) 2 (<1%) 8 (3%) 1 (<1%)
Venous thromboembolic* 6 (2%) 1 (<1%) 13 (5%) 5 (2%)
Arterial thromboembolic* 8 (3%) 6 (2%) 2 (<1%) 0
Fistula* 5 (2%) 3 (1%) 2 (<1%) 2 (<1%)
Congestive heart failure* 3 (1%) 2 (<1%) 1 (<1%) 1 (<1%)
Gastrointestinal perforation* 3 (1%) 2 (<1%) 1 (<1%) 1 (<1%)
Data are number of patients (%). Data are treatment-emergent adverse events occurring in at least 10% of patients or 
of special interest irrespective of cause, according to either preferred terms or *consolidated categories.
Table 2: Treatment-emergent adverse events (safety population)
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hypertension and bleeding—occurred at a higher 
frequency with ramucirumab than with placebo. Yet, the 
analyses of patient-reported out comes indicated no 
negative effect on quality of life. This finding is especially 
important for these patients, because most have a short 
life expectancy.
Previous meta-analyses of second-line chemotherapy for 
patients with metastatic urothelial carcinoma showed that 
improvements in progression-free survival predict 
improvements in overall survival.34 Based on this obser-
vation, and the improvement in objective response noted 
with ramucirumab and docetaxel, we believe our results 
are clinically significant.
Although our findings are positive, the study and the 
data available at the time of publication have limitations. 
Patients were not stratified according to all second-line 
Bellmunt risk factors and, as such, some imbalances were 
noted between treatment groups. A higher proportion of 
patients allocated ramucirumab had liver metastases (30% 
vs 26%) and a total Bellmunt risk score of 3 (18% vs 12%) 
compared with those assigned placebo, which might have 
affected study outcomes. The trial design allowed for 
inclusion of patients after treat ment with an immune-
checkpoint inhibitor. How ever, only two such agents—
atezolizumab (May, 2016) and nivolumab (February, 
2017)—received regulatory approval for urothelial carci-
noma before the end of the enrolment period of this study, 
and this approval was restricted to the USA. As a result, 
enrolment of such patients was limited. Further clinical 
experience with this cohort and with others in future 
studies will be needed to fully understand the efficacy of 
ramucirumab and docetaxel when used after treatment 
with a platinum-based regimen and immune-checkpoint 
inhibitors. Overall, median follow-up in the ITT popu-
lation was fairly short (5 months) at this primary 
progression-free survival analysis, which can be attributed 
to the study population being a subset of the full ITT 
population and the overall rapid disease course leading to 
a short time to progression in patients with urothelial 
carcinoma. Survival data are pending maturity and will be 
informative once available.
Acknowledging the limitations and taken into context, 
the combination of ramucirumab and docetaxel shows 
significant activity without clear deleterious effects on 
quality of life, in a clinical setting of high unmet medical 
need. A high frequency of disease control will be attractive 
for patients for whom alternative chemo therapy options 
are limited and largely ineffective. Data for immune-
checkpoint inhibitors have also become available in this 
setting, resulting in their widespread use in the USA. 
Inconsistencies have been seen with these agents, 
although long-term durable remission occurs in a subset 
of patients, and a survival advantage has been shown for 
pembrolizumab.6 Our trial included 43 patients who 
had previously received immune-checkpoint inhibitors 
(appendix p 13). Two additional patients had been in 
clinical trials before RANGE in which they were randomly 
allocated either an immune-checkpoint inhibitor or 
placebo. Unfortunately, these numbers are small and only 
33 of the 43 patients were included in the primary analysis 
of progression-free survival. However, responses were 
seen with ramucirumab and docetaxel in this population 
(five [36%] of 14 patients), suggesting activity. Further 
studies in this setting are needed. Based on the reported 
efficacy and tolerability, ramucirumab plus docetaxel is 
also an alternative treatment regimen in the setting after 
immune-checkpoint treatment or in patients ineligible for 
treatment with an immune-checkpoint inhibitor.
Future studies might also be of interest to investigate 
potential benefits of combining immune-checkpoint 
inhibitors and antiangiogenic agents. Findings of phase 
2 and phase 3 studies have shown that about 20% of 
patients with platinum-refractory urothelial carcinoma 
achieve an objective response to immune-checkpoint 
inhibition.6–8 Strategies to increase objective responses 
include combi nations of PD-1 or PD-L1 inhibitors with 
other immune-checkpoint inhibitors, chemotherapy, or 
antiangiogenic agents.5,35–38 Ramucirumab in combi-
nation with PD-1 or PD-L1 inhibitors has shown 
promising clinical activity in multiple tumour types, 
including urothelial carcinoma, in the phase 1 setting, 
with no unexpected toxic effects.36,38,39 More work is 
needed to understand combinatorial and sequencing 
approaches of these new classes of treatment for 
urothelial carcinoma.
In conclusion, the findings of the RANGE trial are 
consistent with results from a previous phase 2 study in 
which ramucirumab combined with docetaxel improved 
progression-free survival in patients with platinum-
refractory advanced or metastatic urothelial carcinoma.13 
Up to now, ramucirumab is the only antiangiogenic 
agent with proven clinical activity in this patient 
population and, to our knowledge, RANGE represents 
the first phase 3 study to show a progression-free survival 
advantage over chemotherapy alone. No additive or 
unexpected toxic effects were seen when ramucirumab 
was combined with docetaxel. Together, these phase 2 
and phase 3 data suggest a favourable benefit-to-risk ratio 
for this combination treatment and might represent a 
new regimen for this patient population.
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